Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q86TM3 (
cage
)
29,987
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PTPN6
(protein tyrosine phosphatase nonreceptor type 6), a tyrosine phosphatase, is known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. Previous studies have demonstrated that
PTPN6
expression is relatively elevated in several malignancies. However, the role of
PTPN6
in bladder cancer (BC) remains unclear. The purpose of this study was to explore the prognostic value of
PTPN6
in BC. RNA-seq data from The Cancer Genome Atlas (TCGA) was used to identify the expression level of
PTPN6
in BC. The relationship between clinical pathologic features and
PTPN6
were analyzed with the Wilcoxon signed-rank test. The prognostic and predictive value of
PTPN6
was evaluated by survival analysis and nomogram. Gene Set Enrichment Analysis (GSEA) was conducted to explore the potential molecular mechanisms of
PTPN6
in BC. Finally, Tumor Immune Estimation Resource (TIMER) was applied to investigate the relationship between
PTPN6
and immune cell infiltration in the tumor microenvironment. Results indicated that
PTPN6
was overexpressed in BC tissues compared with normal bladder tissues and was significantly correlated with grade, stage, T, and N. Survival analysis showed that low expression of
PTPN6
was significantly related to the poor overall survival (OS) in BC patients. Coexpression analysis showed that
PTPN6
and
TNFRSF14
(
Tumor necrosis factor receptor superfamily member 14
) have a close correlation in BC. GSEA showed that multiple
cancer-associated
signaling pathways are differentially enriched in the
PTPN6
high expression phenotype. Moreover, the expression level of
PTPN6
was positively associated with the infiltration of B cells, CD4+T cells, dendritic cells, and neutrophils and negatively associated with CD8+ T cells and macrophages in BC. In conclusion, we identified that
PTPN6
may be a novel prognostic biomarker in BC based on the TCGA database. Further clinical trials are needed to confirm our observations and mechanisms underlying the prognostic value of
PTPN6
in BC also deserve further experimental exploration.
...
PMID:The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA. 3245 5
